<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=319805651697215&amp;ev=PageView&amp;noscript=1">


January 13, 2016

Shipments of proprietary technologies support the development of innovative new therapies for cancer, inflammation and infectious disease

Irvine, CA, and Exton, PA, Jan. 13, 2016 - Cryoport, Inc. (NASDAQ: CYRX), ("Company"), the world's leading cryogenic logistics company, and Morphotek® announced that Cryoport is providing end-to-end cold chain logistics support for shipments of Morphotek’s research and development materials.

Morphotek, a subsidiary of Eisai Inc., a global health care pharmaceutical company, is a life science company that develops novel classes of biological-based products to treat cancer, inflammation and infectious diseases. Since its founding in 2000, Morphotek has made extraordinary progress in discovering and developing monoclonal antibodies (mAbs) being studied in diseases using its proprietary technology platforms:
  • Human MORPHODOMA® technology employs an ex vivo immunization process in combination with morphogenics to generate fully human antibodies targeted against disease-associated antigens. The resultant antibodies are fully human with high-affinity and target specificity.
  • Libradoma™ technology generates libraries of hybridomas that can be rapidly screened to identify fully human monoclonal antibodies to known antigens and novel targets for the diagnosis and treatment of diseases in humans. This platform is being widely pursued internally to feed Morphotek’s future therapeutic antibody pipeline.

Global Supply Chain Management Director of Morphotek, Mr. Myron Waskiw, stated, "By selecting Cryoport for our cold chain logistics, we are partnering with the most experienced cryogenic solutions provider. Cryoport understands the critical nature of our shipments, has the advanced capabilities to track conditions and location of our products in transit around the clock, and, importantly, has the intervention capability to mitigate any logistics risks. Cryoport’s solutions and capabilities are critical to the successful development of our therapeutic candidates."

Mark Sawicki, PhD, Chief Commercial Officer of Cryoport, said, "Cryoport is thrilled to have been selected by Morphotek to manage the cold chain logistics supporting research for its biological-based programs to treat cancer, inflammation and infectious diseases. This relationship further solidifies our position as the leading provider of complete cold chain solutions for innovative therapeutics."

Cryoport is currently supporting 52 clinical trials for advanced therapies and regenerative medicines, including 10 in Phase III, for biopharmaceutical companies around the world.

About Cryoport, Inc.

Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. The company provides leading-edge logistics solutions for biologic materials, such as immunotherapies, stem cells, CAR-T cells and reproductive cells for clients worldwide. Leading global companies, such as FedEx, UPS and DHL, have each separately selected Cryoport as the preferred cryogenic logistics provider for time- and temperature-sensitive biological material. Cryoport actively supports points-of-care, CROs, central laboratories, pharmaceutical companies, contract manufacturers and university researchers. For more information, visit www.cryoport.com.

To download Cryoport's investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and more, please click to download from your iPhone and iPad or Android mobile device.

About Morphotek

Morphotek®, Inc., a subsidiary of Eisai Inc., is a biopharmaceutical company specializing in the development of protein and antibody products through the use of a novel and proprietary gene evolution technology. The technology has been successfully applied to a broad variety of cell lines and organisms to yield genetically diverse offspring that are suitable for pharmaceutical product development in the areas of antibody therapeutics, protein therapeutics, product manufacturing, drug target discovery, and improved output traits for commercial applications.  The company is currently focusing its platform on the development and manufacturing of therapeutic antibodies for the treatment of cancer, inflammation and infectious disease.  For more information, please visit www.morphotek.com.

About Eisai Inc.

At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer’s disease, epilepsy and metabolic disorders). To learn more about Eisai Inc., please visit us at www.eisai.com

Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as a global demand chain organization that includes manufacturing facilities in Maryland and North Carolina. Eisai’s global areas of R&D focus include neuroscience; oncology; metabolic disorders; vascular, inflammatory and immunological reaction; and antibody-based programs.

Morphotek®, MORPHODOMA®, Libradoma™ are trademarks of Eisai Co. Ltd.

Cryoport Forward Looking Statements 
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company's business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2015. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Cryoport Investor Contacts:
Todd Fromer / Garth Russell
tfromer@kcsa.com / grussell@kcsa.com
P: 1 212-682-6300

Morphotek Contact:
Myron Waskiw
Director, Global Supply Chain Management